Annals of Surgical Oncology

, Volume 14, Issue 10, pp 2702–2713 | Cite as

A Systematic Review and Meta-analysis of the Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Gastric Cancer

  • Tristan D. YanEmail author
  • Deborah Black
  • Paul H. Sugarbaker
  • Jacqui Zhu
  • Yutaka Yonemura
  • George Petrou
  • David L. Morris
Gastrointestinal Oncology



The purpose of this systematic review and meta-analysis was to determine the effectiveness and safety of adjuvant intraperitoneal chemotherapy for patients with locally advanced resectable gastric cancer.


Studies eligible for this systematic review included those in which patients with gastric cancer were randomly assigned to receive surgery combined with intraperitoneal chemotherapy versus surgery without intraperitoneal chemotherapy. There were no language restrictions. After independent quality assessment and data extraction, data were pooled for meta-analysis.


Thirteen reports of randomized controlled trials (RCTs) were included for quality appraisal and data extraction. Ten reports were judged to be of fair quality and subjected to meta-analysis. A significant improvement in survival was associated with hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) alone (hazard ratio [HR] = 0.60; 95% CI = 0.43 to 0.83; p = 0.002) or HIIC combined with early postoperative intraperitoneal chemotherapy (EPIC) (HR = 0.45; 95% CI = 0.29 to 0.68; p = 0.0002). There was a trend towards survival improvement with normothermic intraoperative intraperitoneal chemotherapy (p = 0.06), but this was not significant with either EPIC alone or delayed postoperative intraperitoneal chemotherapy. Intraperitoneal chemotherapy was also found to be associated with higher risks of intra-abdominal abscess (RR = 2.37; 95% CI = 1.32 to 4.26; p = 0.003) and neutropenia (RR = 4.33; 95% CI = 1.49 to 12.61; p = 0.007).


The present meta-analysis indicates that HIIC with or without EPIC after resection of advanced gastric primary cancer is associated with improved overall survival. However, increased risk of intra-abdominal abscess and neutropenia are also demonstrated.


Gastric carcinoma Intraperitoneal chemotherapy 



All authors declare that there are no potential conflicts of interest. Tristan D. Yan, a surgical oncology research fellow, is partly sponsored by the Foundation for Applied Research in Gastrointestinal Oncology. The authors gratefully acknowledge Drs/Profs M. Ikeguchi, W. Yu, H. Rosen, L. Xin, Y. Yonemura, G. Wei and Z. Gao for providing advice or additional unpublished information regarding their respective trials. We thank Profs L. Xin and Y. Yonemura for translating studies published in Chinese and Japanese languages.


  1. 1.
    Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003;56:1–9PubMedCrossRefGoogle Scholar
  2. 2.
    Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33–64PubMedCrossRefGoogle Scholar
  3. 3.
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106–30PubMedCrossRefGoogle Scholar
  4. 4.
    Ohtsu A, Yoshida S, Saijo N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol 2006;24:2188–96PubMedCrossRefGoogle Scholar
  5. 5.
    NHS Centre for Reviews and Dissemination. Undertaking Systemic Reviews of Research on Effectiveness: CRD’s Guidance for those Carrying Out or Commissioning Reviews. CRD Report 4 (2nd edn). York: NHS Centre for Reviews and Dissemination; 2001Google Scholar
  6. 6.
    Dixon E, Hameed M, Sutherland F, et al. Evaluating meta-analyses in the general surgical literature: a critical appraisal. Ann Surg 2005;241:450–9PubMedCrossRefGoogle Scholar
  7. 7.
    Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815–34PubMedCrossRefGoogle Scholar
  8. 8.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–188PubMedCrossRefGoogle Scholar
  9. 9.
    Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34PubMedGoogle Scholar
  10. 10.
    Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–58PubMedCrossRefGoogle Scholar
  11. 11.
    Hamazoe R, Maeta M, Kaibara N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer - final results of a randomised controlled study. Cancer 1994;73:2048–52PubMedCrossRefGoogle Scholar
  12. 12.
    Fujimoto S, Takahashi M, Mutou T, et al. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 1999;85:529–34PubMedCrossRefGoogle Scholar
  13. 13.
    Yonemura Y, de Aretxabala X, Fujimura T, et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomised controlled study. Hepatogastroenterol 2001;48:1776–82Google Scholar
  14. 14.
    Zhang W, Su D, Wang K, et al. Clinical study in prophylactic use of intraperitoneal hyperthermic chemoperfusion for the prevention of peritoneal metastasis in patients with advanced gastric carcinoma. Shanxi Yiyao Zazhi 1998;27:67–9Google Scholar
  15. 15.
    Takahashi T, Hagiwara A, Shimotsuma M, et al. Prophylaxis and treatment of peritoneal carcinomatosis: intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles. World J Surg 1995;19:565–9PubMedCrossRefGoogle Scholar
  16. 16.
    Shimoyama S, Shimizu N, Kaminishi M. Type-oriented intraoperative and adjuvant chemotherapy and survival after curative resection of advanced gastric cancer. World J Surg 1999;23:284–91PubMedCrossRefGoogle Scholar
  17. 17.
    Miyashiro I, Furukawa H, Sasako M, et al. No survival benefit with adjuvant chemotherapy for serosal-positive gastric cancer: Randomised trial of adjuvant chemotherapy with cisplatin followed by oral fluorouracil in serosa-positive gastric cancer - Japan Clinical Oncology Group 9206-2. Proc ASCO-GI 84 (abstr 4), 2005Google Scholar
  18. 18.
    Rosen HR, Jatzko G, Repse S, et al. Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomised multi-center trial of the Austrian Working Group for Surgical Oncology. J Clin Oncol 1998;16:2733–8PubMedGoogle Scholar
  19. 19.
    Yu W, Whang I, Chung HY, et al. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomised trial. World J Surg 2001;25:985–90PubMedCrossRefGoogle Scholar
  20. 20.
    Wei G, Fang GE, Bi JW, et al. Efficacy of intraoperative hypotonic peritoneal chemo-hyperthermia combined with early postoperative intraperitoneal chemotherapy on gastric cancer. Ai Zheng 2005;24:478–82PubMedGoogle Scholar
  21. 21.
    Gao Z, Jiang Z, Zhou F. Clinical surgery of early intraperitoneal hyperthermic chemoperfusion for gastric cancer patients after operation. Zhonggou Zhongliu Linchuang 2002;29:294–5Google Scholar
  22. 22.
    Sautner T, Hofbauer F, Depisch D, et al. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 1994;12:970–4PubMedGoogle Scholar
  23. 23.
    Zuo Y, Xu M, Shen D, et al. Postoperative intraperitioneal hyperthermic chemoperfusion combined with intravenous chemotherapy for 82 advanced gastric cancer patients. Zhonghua Zhongliu Zazhi 2004;26:247–9PubMedGoogle Scholar
  24. 24.
    Tan C, Wang X, Xu Y, et al. Study for prevention of peritoneal dissemination of advanced gastric cancer by intraperitoneal thermochemotherapy. Shiyong Zhongliu Zazhi 2000;15:165–7Google Scholar
  25. 25.
    Ikeguchi M, Kondou A, Oka A, et al. Effects of continuous hyperthermic peritoneal perfusion on prognosis of gastric cancer with serosal invasion. Eur J Surg 1995;161:581–6PubMedGoogle Scholar
  26. 26.
    Kaibara N, Hamazoe R, Iitsuka Y, et al. Hyperthermic peritoneal perfusion combined with anticancer chemotherapy as prophylactic treatment of peritoneal recurrence of gastric cancer. Hepatogastroenterol 1989;36:75–8Google Scholar
  27. 27.
    Koga S, Hamazoe R, Maeta M, et al. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer 1988;61:232–7PubMedCrossRefGoogle Scholar
  28. 28.
    Fujimura T, Yonemura Y, Muraoka K, et al. Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomised controlled study. World J Surg 1994;18:150–5PubMedCrossRefGoogle Scholar
  29. 29.
    Hagiwara A, Takahashi T, Kojima O, et al. Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet 1992;339:629–1PubMedCrossRefGoogle Scholar
  30. 30.
    Takahashi T, Hagiwara A, Shimotsuma M. Intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles for patients with advanced gastric cancer. Eur J Surg Oncol 1994;20:183–4PubMedGoogle Scholar
  31. 31.
    Yu W, Whang I, Averbach A, et al. Morbidity and mortality of early postoperative intraperitoneal chemotherapy as adjuvant therapy for gastric cancer. Am Surg 1998;64:1104–8PubMedGoogle Scholar
  32. 32.
    Yu W, Whang I, Suh I, et al. Prospective randomised trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 1998;228:347–54PubMedCrossRefGoogle Scholar
  33. 33.
    Yu W, Sugarbaker P, Whang I. Randomised controlled trial of early postoperative intraperitoneal chemotherapy in gastric cancer: a preliminary report. Reg Cancer Treat 1994;2:90–3Google Scholar
  34. 34.
    Schiessel R, Funovics J, Schick B, et al. Adjuvant intraperitoneal cisplatin therapy in patients with operated gastric carcinoma: results of a randomised trial. Acta Med Austriaca 1989;16:68–9PubMedGoogle Scholar
  35. 35.
    Xu DZ, Zhan YQ, Sun XW, et al. Meta-analysis of intraperitoneal chemotherapy for gastric cancer. World J Gastroenterol 2004;10:2727–30PubMedGoogle Scholar
  36. 36.
    Weisberger AS, Levine B, Storaasli JP. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. JAMA 1955;159:1704–7Google Scholar
  37. 37.
    Jones RB, Myers CE, Guarino AM, et al. High volume intraperitoneal chemotherapy (“belly bath”) for ovarian cancer. Pharmacologic basis and early results. Cancer Chemother Pharmacol 1978;1:161–6PubMedCrossRefGoogle Scholar
  38. 38.
    Jaaback K, Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev CD005340, 2006Google Scholar
  39. 39.
    Verwaal VJ, van Ruth S, de Bree E, et al. Randomised trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737–43PubMedCrossRefGoogle Scholar
  40. 40.
    Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 2006;7:69–76PubMedCrossRefGoogle Scholar
  41. 41.
    Yan TD, Black D, Savady R, et al. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol doi:10.1245/s10434-006-9182-x, 2006Google Scholar
  42. 42.
    Yan TD, Welch L, Black D, et al. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol doi:10.1093/annonc/mdl428, 2006Google Scholar
  43. 43.
    Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20PubMedCrossRefGoogle Scholar
  44. 44.
    MacDonald JS, Malley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725–9PubMedCrossRefGoogle Scholar
  45. 45.
    Cascinu S, Labianca R, Barone C, et al Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin and Epidoxorubibin in a randomized controlled trial. J Natl Cancer Inst doi: 10.1093/jnci/djk131, 2007Google Scholar
  46. 46.
    Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995;221:124–32PubMedCrossRefGoogle Scholar
  47. 47.
    Los G, Mutsaers PH, Lenglet WJ, et al. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol 1990;25:389–94PubMedCrossRefGoogle Scholar
  48. 48.
    Yonemura Y, Kawamura T, Bandou E, et al. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg 2005;92:370–5PubMedCrossRefGoogle Scholar
  49. 49.
    Glehen O, Schreiber V, Cotte E, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg 2004;139:20–6PubMedCrossRefGoogle Scholar
  50. 50.
    Hall JJ, Loggie BW, Shen P, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg 2004;8:454–63PubMedCrossRefGoogle Scholar
  51. 51.
    Armstrong D, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:77–9CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2007

Authors and Affiliations

  • Tristan D. Yan
    • 1
    • 2
    Email author
  • Deborah Black
    • 3
  • Paul H. Sugarbaker
    • 2
  • Jacqui Zhu
    • 4
  • Yutaka Yonemura
    • 5
  • George Petrou
    • 1
  • David L. Morris
    • 1
  1. 1.Department of SurgeryUniversity of New South Wales, St George HospitalSydneyAustralia
  2. 2.Department of Surgical OncologyWashington Cancer Institute, Washington Hospital CenterWashingtonUSA
  3. 3.School of Public Health and Community MedicineUniversity of New South WalesSydneyAustralia
  4. 4.School of MedicineUniversity of New South WalesSydneyAustralia
  5. 5.Department of Gastric CancerShizuoka Cancer CenterShizuokaJapan

Personalised recommendations